OTC · CIK 0000908259
OTLC Oncotelic Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Jul 23, 2026. Close $0.02 on Oct 9, 2026, 0% from the 52-week low and -82% from the high.
In brief
Oncotelic Therapeutics, Inc. (OTLC) has 14 SEC Form 4 filings on file from 6 insiders, the latest filed on Jul 23, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
6 open-market trades have been scored at OTLC. The newest: Vuong Trieu (CHAIRMAN AND CEO) bought $10k of stock on Jul 1, 2026, filed Jul 2, 2026, scored 41 (moderate). The largest of the 6 shown: Vuong Trieu (CHAIRMAN AND CEO) bought $15k on Jun 15, 2026, scored 36 (weak). 2 insiders bought within 14 days of each other around Jul 1, 2026.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Oncotelic Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 41Moderate | Vuong Trieu CHAIRMAN AND CEO buy | $10k 240,000 shares | +0% | +33% from low-64% from high | |
| 41Moderate | Vuong Trieu CHAIRMAN AND CEO buy | $11k 255,000 shares | +0% | +67% from low-55% from high | |
| 41Moderate | Amit B. Shah CFO buy | $1,000 20,000 shares | +6% | +67% from low-55% from high | |
| 36Weak | Vuong Trieu CHAIRMAN AND CEO buy | $15k 335,759 shares | +0% | +33% from low-64% from high | |
| 24Weak | Vuong Trieu CHAIRMAN AND CEO buy | $994 198,737 shares | +0% | +150% from low-29% from high | |
| 20Weak | Vuong Trieu CHAIRMAN AND CEO buy | $8,627 298,499 shares | +0% | - |
Transactions
Every row filed, 19 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 10, 2026 | Seymour Howard Fein CRO/CMO | AGrant or award Restricted stock Unitsderivative | +250 | $0.00 | $0 | 250 | Jul 23, 2026 |
| Jul 10, 2026 | Steven W King director | AGrant or award Restricted stock Unitsderivative | +250 | $0.00 | $0 | 250 | Jul 21, 2026 |
| Jul 10, 2026 | Anthony E Maida III DIRECTOR AND CMO - TRANS. MED. | AGrant or award Restricted stock Unitsderivative | +1,500 | $0.00 | $0 | 1,500 | Jul 14, 2026 |
| Jul 10, 2026 | Amit B. Shah CFO | AGrant or award Restricted stock Unitsderivative | +1,500 | $0.00 | $0 | 1,500 | Jul 14, 2026 |
| Jul 10, 2026 | Saran Saund CBO | AGrant or award Restricted stock Unitsderivative | +1,500 | $0.00 | $0 | 1,500 | Jul 14, 2026 |
| Jul 10, 2026 | Vuong Trieu CHAIRMAN AND CEO | AGrant or award Restricted stock Unitsderivative | +2,000 | $0.00 | $0 | 2,000 | Jul 14, 2026 |
| Jul 1, 2026 | Vuong Trieu CHAIRMAN AND CEO | POpen-market purchase Common Stock | +240,000 | $0.04 | $10k | 94,124,319 | Jul 2, 2026 |
| Jun 24, 2026 | Vuong Trieu CHAIRMAN AND CEO | POpen-market purchase Common Stock | +115,000 | $0.05 | $5,175 | 93,884,319 | Jun 24, 2026 |
| Jun 23, 2026 | Vuong Trieu CHAIRMAN AND CEO | POpen-market purchase Common Stock | +75,000 | $0.05 | $3,375 | 93,769,319 | Jun 24, 2026 |
| Jun 22, 2026 | Vuong Trieu CHAIRMAN AND CEO | POpen-market purchase Common Stock | +65,000 | $0.05 | $2,925 | 93,694,319 | Jun 24, 2026 |
| Jun 22, 2026 | Amit B. Shah CFO | POpen-market purchase Common Stock | +20,000 | $0.05 | $1,000 | 378,837 | Jun 22, 2026 |
| Jun 17, 2026 | Vuong Trieu CHAIRMAN AND CEO | POpen-market purchase Common Stock | +239,759 | $0.04 | $11k | 93,629,319 | Jun 17, 2026 |
| Jun 15, 2026 | Vuong Trieu CHAIRMAN AND CEO | POpen-market purchase Common Stock | +96,000 | $0.05 | $4,320 | 93,389,560 | Jun 17, 2026 |
| Jan 22, 2026 | Vuong Trieu CHAIRMAN AND CEO | AGrant or award Series A Convertible Preferred Stockderivative | +4,426 | $0.00 | $0 | 8,491 | Jan 26, 2026 |
| Nov 17, 2025 | Vuong Trieu CHAIRMAN AND CEO | AGrant or award Series A Convertible Preferred Stockderivative | +4,065 | $0.00 | $0 | 4,065 | Nov 19, 2025 |
| Jul 10, 2025 | Vuong Trieu CHAIRMAN AND CEO | POpen-market purchase Common Stock | +104,000 | $0.01 | $520 | 93,293,560 | Jul 10, 2025 |
| Jul 9, 2025 | Vuong Trieu CHAIRMAN AND CEO | POpen-market purchase Common Stock | +1 | $0.01 | $0 | 93,293,561 | Jul 10, 2025 |
| Jul 8, 2025 | Vuong Trieu CHAIRMAN AND CEO | POpen-market purchase Common Stock | +94,736 | $0.01 | $474 | 93,388,297 | Jul 10, 2025 |
| Nov 22, 2024 | Vuong Trieu CHAIRMAN AND CEO | POpen-market purchase Common Stock | +298,499 | $0.03 | $8,627 | 92,842,716 | Nov 26, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Seymour Howard FeinCRO/CMO
- Steven W Kingdirector
- Anthony E Maida IIIDIRECTOR AND CMO - TRANS. MED.
- Saran SaundCBO
- Amit B. ShahCFO
- Vuong TrieuCHAIRMAN AND CEO
Questions about OTLC
Answered from the filings on this page, as of the latest one.
Are insiders buying OTLC?
No. In the last 90 days no insider at Oncotelic Therapeutics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade OTLC on the open market?
Vuong Trieu (CHAIRMAN AND CEO) bought $10k of OTLC on Jul 1, 2026 and filed the Form 4 on Jul 2, 2026. InsiderTell scored 41 (moderate), with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at Oncotelic Therapeutics, Inc.?
6 people have filed a Form 4 at Oncotelic Therapeutics, Inc., among them Seymour Howard Fein (CRO/CMO), Steven W King (director), Anthony E Maida III (DIRECTOR AND CMO - TRANS. MED.). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.